On Thursday, President Trump announced that his administration had a goal to end the HIV epidemic in the US within 10 years, announcing that his administration had successfully worked with a pharmaceutical company to initiate a historic donation to eliminate the HIV problem in America.
Trump stated on Twitter: “Good news today: My administration has only secured a historic donation of HIV prevention drugs from Gilead to help increase access to PrEP for the uninsured and those at risk. Will help us to achieve our goal to end the HIV epidemic in America! “
Department of Healthcare more specific:
Health Care Secretary Alex M. Azar II today announced that the drug company, as a result of discussions between Trump Administration and Gilead Sciences, Inc., has agreed to donate pre-exposure prophylaxis (PrEP) drugs for up to 200,000 people each year for up to 11 years. PrEP is used to reduce the risk of HIV infection in individuals at higher risk for HIV. It has been shown to reduce the risk of new infection by up to 97 percent when taken consistently.
The agreement between the US Department of Health and Human Services and Gilead will be until December 31, 2025 and possibly until December 31, 2030, and will provide drugs to treat individuals at risk of HIV and who are uninsured. This donation will deliver Gilead’s PrEP drugs Truvada, which currently has a list price of over $ 20,000 per patient per year, up to 200,000 people per year, including in the states and counties identified as priority areas in the Trump Administration. plan – PDF to end the HIV epidemic in America.
Gilead will donate Truvada until its second generation HIV prevention medication, Descovy, becomes available. At that time, Gilead will donate Descovy. The deal should end after 11 years, or when a generic version of Descovy becomes commercially available, whichever comes first. The government has agreed to cover the costs of distributing the drugs.
Azar issued a statement:
Ensuring this commitment is an important step in the Trump administration’s efforts to use the prevention and treatment tools that we must complete the hive epidemic in America in 2030. Under President Trump’s leadership, HHS worked with Gilead to secure prevention medication for individuals who otherwise would not be able to access or afford this important treatment. The majority of Americans at risk and who can protect themselves with PrEP still do not get the medicine. This agreement will help close this gap considerably and deliver to President Trump’s promise to end the HIV epidemic in America.
According to the CDC: “By the end of 2016, an estimated 1.1 million people aged 13 years had older HIV infection in the United States, including estimated 162,500 (14%) people whose infections had not been diagnosed. about 1.8 million new cases of HIV in 2017. About 36.9 million people live with HIV worldwide. An estimated 940,000 people died of AIDS-related diseases in 2017. ”